JP2024517879A5 - - Google Patents
Info
- Publication number
- JP2024517879A5 JP2024517879A5 JP2023568386A JP2023568386A JP2024517879A5 JP 2024517879 A5 JP2024517879 A5 JP 2024517879A5 JP 2023568386 A JP2023568386 A JP 2023568386A JP 2023568386 A JP2023568386 A JP 2023568386A JP 2024517879 A5 JP2024517879 A5 JP 2024517879A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- directed
- target
- receptor
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185951P | 2021-05-07 | 2021-05-07 | |
| US63/185,951 | 2021-05-07 | ||
| PCT/CA2022/050712 WO2022232943A1 (en) | 2021-05-07 | 2022-05-06 | Chelators for radiometals and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517879A JP2024517879A (ja) | 2024-04-23 |
| JP2024517879A5 true JP2024517879A5 (enExample) | 2025-05-09 |
Family
ID=83931919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568386A Pending JP2024517879A (ja) | 2021-05-07 | 2022-05-06 | 放射性金属用キレート剤ならびにその製造方法および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240254085A1 (enExample) |
| EP (1) | EP4334290A4 (enExample) |
| JP (1) | JP2024517879A (enExample) |
| AU (1) | AU2022271362A1 (enExample) |
| CA (1) | CA3217801A1 (enExample) |
| WO (1) | WO2022232943A1 (enExample) |
| ZA (1) | ZA202310013B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024235273A1 (zh) * | 2023-05-15 | 2024-11-21 | 成都社泰医疗科技有限公司 | 多靶向化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020186328A1 (en) * | 2019-03-20 | 2020-09-24 | The University Of British Columbia | Chelators and methods of making and using same |
-
2022
- 2022-05-06 CA CA3217801A patent/CA3217801A1/en active Pending
- 2022-05-06 JP JP2023568386A patent/JP2024517879A/ja active Pending
- 2022-05-06 US US18/559,132 patent/US20240254085A1/en active Pending
- 2022-05-06 EP EP22798482.0A patent/EP4334290A4/en active Pending
- 2022-05-06 AU AU2022271362A patent/AU2022271362A1/en active Pending
- 2022-05-06 WO PCT/CA2022/050712 patent/WO2022232943A1/en not_active Ceased
-
2023
- 2023-10-26 ZA ZA2023/10013A patent/ZA202310013B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514784A5 (enExample) | ||
| Altunay et al. | HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging | |
| Wei et al. | ImmunoPET: concept, design, and applications | |
| Orlova et al. | Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors | |
| CN108136012B (zh) | 靶向分子的抗原结合构建体 | |
| AU2018388467B2 (en) | Radiolabeling of polypeptides | |
| Milenic et al. | Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications | |
| Tolmachev | Imaging of HER-2 overexpression in tumors for guiding therapy | |
| De Pauw et al. | Current status and future expectations of nanobodies in oncology trials | |
| Levêque et al. | Pharmacokinetics of therapeutic monoclonal antibodies used in oncology | |
| Tran et al. | 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors | |
| TR201901824T4 (tr) | Rs7 Antikorları | |
| JP2023537002A5 (enExample) | ||
| HK1217957A1 (zh) | 靶向人前列腺特异性膜抗原的j591微抗体和双抗体 | |
| JP2022547483A5 (enExample) | ||
| Boskovitz et al. | Monoclonal antibodies for brain tumour treatment | |
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| JP7812336B2 (ja) | 分子連結法または分子工学のためのタンデムリピートがん標的化ペプチドおよびがんセラノスティクスにおけるその使用 | |
| US20220211886A1 (en) | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer | |
| JP2024530166A5 (enExample) | ||
| CN115103633A (zh) | 使用多种成像剂的成像方法 | |
| Vorobyeva et al. | Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy | |
| Orlova et al. | Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2: 342, a potential agent for imaging of HER2 expression in malignant tumors | |
| WO2019040740A1 (en) | IMMUNO IMAGING IN VIVO OF INTERFERON GAMMA | |
| AU2009201892A1 (en) | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |